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Human prion diseases are infectious and invariably fatal neurodegenerative diseases, 
including sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and 
variant CJD (vCJD) which is caused by interspecies transmission of prions from cattle 
infected by bovine spongiform encephalopathy. Development of a biochemical assay for 
the sensitive, specific, early and non-invasive detection of prions in blood of patients 
affected by prion disease is a top medical priority to increase the safety of the blood 
supply. vCJD has already been transmitted from human-to-human by blood transfusion 
and the number of asymptomatic carriers of vCJD in the UK alone is estimated to be 1 
in 2,000 people. In this study we used the protein misfolding cyclic amplification (PMCA) 
technique to analyze blood samples from 14 cases of vCJD and 153 controls, including 
patients affected by sCJD, other neurodegenerative or neurological disorders as well as 
healthy subjects. Our results show that we can detect PrPSc with 100% sensitivity and 
specificity in the tested vCJD samples. Detection was possible in any of the blood 
fractions analyzed and can be done with as little as a few µL of sample volume. The 
PrPSc concentration in blood was estimated to be ~0.5 pg/mL. Our findings suggest that 
PMCA may be useful for pre-mortem non-invasive diagnosis of vCJD and to identify 
prion contamination of the blood supply. Further studies are needed to fully validate the 
technology and investigate the earliest time during the pre-clinical phase of vCJD when 
PrPSc is detectable in blood. 
  
 
Human prion diseases are infectious and invariably fatal neurodegenerative diseases, 
including sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and 
variant CJD (vCJD), which is associated with the consumption of cattle infected with 
bovine spongiform encephalopathy (1, 2). Currently there is not a regulatory approved 
assay for sensitive, objective and non-invasive biochemical diagnosis of these diseases. 
This is a major problem for public health, because prion diseases are known to be 
transmitted iatrogenically between human-to-human and because asymptomatic 
carriers may far outnumber the clinically affected individuals, due to the long pre-
symptomatic stage of the disease, which may span several decades (3).  
The infectious agent responsible for these diseases, termed prion, appears to be 
composed exclusively of a conformationally altered form of a naturally occurring protein, 
named PrPSc, which has the exceptional ability to infect individuals and propagate in the 
body without the need for genetic material (4). PrPSc is not only the main component of 
the infectious agent and the likely culprit of neurodegeneration, but is also the best 
surrogate marker for the disease. A major challenge for early diagnosis based on PrPSc 
detection is that this marker is present at high levels only in the CNS at late stages of 
the disease. However, several lines of evidence indicate that prions are also present in 
small quantities in peripheral tissues and biological fluids, such as lymphoid organs, 
CSF and blood (5, 6). Detection of PrPSc in blood is very challenging as little is known 
about its quantity, nature and distribution in this fluid. Based on animal infectivity studies 
it is estimated that in rodent plasma and buffy coat fractions there is as little as 1-10 
LD50 infectious units in 1 mL of whole blood, which translates into the equivalent to a 10
-
7 - 10-9 dilution of the brain (7). Moreover, both high levels of normal PrPC found in these 
fluids as well as uncertainty on the biochemical and structural properties of blood-
derived PrPSc (8-12), would make it very difficult to develop a diagnostic test relying on 
existing biochemical and immunological methods for detecting PrPSc. In the case of CJD 
it is also imperative that an effective test must not only have high sensitivity but also be 
extremely specific. Considering that no treatment is available for this disease, it is not 
ethically acceptable to have a test with high frequency of false positives.  
Our strategy to achieve sensitive and specific detection of PrPSc is to use an 
amplification technology that reproduces PrPSc replication in vitro (13). This system is 
called PMCA (Protein Misfolding Cyclic Amplification) and consists of cycles of 
accelerated prion replication combining phases of PrPSc growing with fragmentation of 
the polymers to increase the number of seeding-competent units. The cyclic nature of 
the system permits employing as many cycles as required to reach the amplification 
state needed for the detection of PrPSc in a particular sample (13, 14). We have 
previously reported proof-of-concept experiments in which the technology was applied 
to replicate the misfolded protein from diverse species (15). The technology has been 
automated, leading to a dramatic increase on efficiency of amplification. In its most 
current form in vCJD samples (16), one round of 96 PMCA cycles (2 days) results in the 
ability to detect up to a 100 million-fold (108) dilution of brain, whereas after 2 rounds we 
reached the highest detectability possible, which is around 10 billion-fold (1010) dilution. 
Moreover, our results demonstrate that PMCA is capable of detecting as little as 
approximately 26 monomers of PrP (17, 18), which according to recent data on the 
minimal size of the infectious particle (19), would correspond to a single particle of 
oligomeric infectious PrPSc. These data demonstrates that PMCA has a similar power of 
amplification as PCR techniques used to amplify DNA and opens great possibilities for 
development of a highly sensitive detection of PrPSc. Indeed, we have demonstrated 
that after amplification we can detect PrPSc in blood of hamsters experimentally infected 
with scrapie during both the symptomatic (20) and pre-symptomatic phases of the 
disease (21) as well as in urine of humans affected by vCJD (16). A recent report 
showed PrPSc detection by PMCA in white blood cells of few patients affected by vCJD 
(22). Using an ovine PrPC substrate for the PMCA reaction, this study showed a limit of 
detection equivalent to 10-7 brain dilution and positive PrPSc detection in 3 of the 4 vCJD 
samples tested, suggesting the possibility of the absence of prionemia in certain 
patients (22). The major goal of our study was to develop a more sensitive PMCA assay 
for PrPSc detection in vCJD samples and use it to evaluate the presence of prions in 
blood from patients affected by this disease, estimate sensitivity and specificity as well 
as the approximate quantity of PrPSc present in vCJD blood. 
  
RESULTS 
To begin analyzing the possibility to detect vCJD PrPSc in blood by PMCA, we first 
performed spiking experiments diluting vCJD brain homogenate into healthy whole 
blood in order to optimize conditions and evaluate the limit of sensitivity. As observed 
before in our experiments to detect PrPSc in animal blood, this fluid drastically inhibited 
PMCA reaction (20, 21). For this reason, it is necessary to process the blood samples to 
enrich in PrPSc and remove other blood components that interfere with PMCA. The 
process consists of a centrifugation in the presence of sarkosyl, followed by washing in 
PBS (Fig. 1). The resulting material was subjected to sequential rounds of PMCA using 
a substrate of transgenic mice Tg6816 brain homogenate expressing human PrP with 
Met/Met genotype at position 129 (TgHuPrP(129MM)). After the first round of PMCA we 
can detect up to a 10-6 final dilution of vCJD brain homogenate spiked in whole blood 
(Fig. 2). This level of detection is clearly lower than the one observed when vCJD brain 
homogenate was diluted directly in conversion buffer (16), suggesting that even despite 
the cleaning procedure, there is still some interference of blood components. After 2 
rounds of PMCA we can detect PrPSc up to a 10-9 dilution and after 3 rounds we reach 
the maximum level of detection, equivalent to a 10-10 dilution of the brain (Fig. 2).   
We then analyzed blood from 14 patients suffering from vCJD and compared it to 
samples from people affected by other neurodegenerative (62 samples) or non-
degenerative neurological disorders (26 samples) and healthy individuals (49 samples) 
(Table 1). Our results show that most of vCJD blood samples analyzed were positive 
after 2 rounds of PMCA and all after 3 rounds, whereas none of the control samples 
gave any signal, even after 5 rounds of PMCA (Fig. 3, Table 1). These data indicate that 
the PMCA technology has a 100% sensitivity (95% confidence interval 76.8-100%) and 
specificity (95% confidence interval 97.6-100%) for detection of PrPSc in blood of vCJD 
patients. To analyze whether detection of PrPSc in blood is specific for vCJD compared 
to other forms of human prion diseases, we studied samples from sCJD blood. The 
results showed that none of the 6 samples tested of sCJD whole blood was positive for 
PMCA even after 5 rounds of amplification (Fig. 3). These later results do not 
necessarily mean that there is not PrPSc in sCJD blood, but that with this set of PMCA 
conditions it is not detectable. Indeed, a spiking experiment in which healthy blood 
containing different dilutions of sCJD brain homogenate showed no detection of PrPSc 
even at the lowest dilutions used (Fig. S1). We are currently optimizing a different set of 
PMCA conditions to efficiently detect sCJD prions.  
To analyze the blood fraction that carries PrPSc, we obtained plasma and white cells  
from 2 additional cases of vCJD. PrPSc was detectable in both of these fractions after a 
similar number of amplification cycles (Fig. 4), indicating that the amount of prions in 
plasma and cells is similar. However, we cannot rule out substantial differences in the 
quantity of PrPSc in different blood fractions that were masked by the very high 
efficiency of the assay. Also, PrPSc was detectable in whole blood from a patient 
collected at two different times during the symptomatic disease (Fig. 4 lanes 5 and 6). 
We analyzed similar fractions of sCJD blood, confirming the absence of prions able to 
replicate in the setting used to detect vCJD prions (Fig. 4B).   
We also analyzed the molecular typing of prions amplified from blood by PMCA (Fig. 
S2). As expected, the material amplified from blood has the same type 2B pattern 
displayed by prions from vCJD brain homogenate, in contrast to the type 1 and 2 
patterns of classical sCJD. 
To estimate the minimum volume of blood required for our assay, we tested different 
quantities of whole blood from 2 different vCJD patients. Our results show that as little 
as 3 or even 0.3 µl of blood are sufficient to readily detect PrPSc in human vCJD blood 
after PMCA amplification (Fig. 5A). The differences in the minimum volume of blood 
needed to detect the signal for the 2 distinct samples tested likely reflect the dissimilar 
amounts of prions present in different blood samples. However, we cannot rule out that 
some samples may have also different amounts of blood components that interfere with 
the PMCA reaction. Reduction of the volume of material used also avoided the need of 
a pre-cleaning step, since the concentration of PMCA inhibitors present in blood is 
reduced to a level that does not significantly interfere with the reaction. Indeed, in 
samples of healthy blood spiked with a 10-8 dilution of vCJD brain homogenate, the 
signal in the second PMCA round was higher when the volume of sample was lower 
(Fig. 5A). Elimination of the pre-cleaning step is important for practical and routine use 
of the technology in blood detection since this step is time- and effort-demanding. The 
small minimum volume of blood needed for PrPSc detection added to the known ability 
of PrPSc to bind to a variety of surfaces (23-25), led us to hypothesize that just by 
placing a blood sample in the PMCA tube, maybe enough prions would bind to the tube 
and enable prion replication in a PMCA reaction. To investigate this possibility, 100 µl of 
whole blood from 2 different patients affected by vCJD, as well as 5 healthy controls 
and normal blood spiked with a 10-5 and a 10-9 final dilution of vCJD brain homogenate 
were incubated in PMCA tubes for 1h at room temperature. Thereafter, the entire 
volume of the samples was removed and 100 µl of PMCA substrate (10% 
TgHuPrP(129MM)) was added to the same tube. After serial rounds of PMCA the 
presence of PrPSc was detected by western blots after PK digestion. The results clearly 
showed that a PrPSc signal was detected in both vCJD blood samples, as well as in the 
positive controls spiked with vCJD brain homogenate (Fig. 5B). Interestingly, the round 
in which the samples of vCJD blood were detected after tube binding of the agent was 
the same as by using the standard protocol of centrifugation in detergent. Indeed, 
sample vCJD4 was detectable in both cases in round 2 and sample vCJD7 was 
detectable after 3 rounds of PMCA (compare Fig. 3 and 5B). No signal was detectable 
in any of the healthy controls. These results may enable the implementation of a simpler 
procedure for PrPSc detection in blood, leading to substantial savings of time and 
samples, but the robustness of the assay need to be confirmed by analyzing larger 
number of vCJD blood samples. The efficient detection of PrPSc in tubes that were 
simply exposed to the infectious material shows once again the similar power of 
amplification of PMCA compared to PCR reactions.     
Finally, to estimate the quantity of PrPSc present in vCJD blood, we used the 
quantitative PMCA technology which compares the number of cycles required to detect 
the signal with those of blood spiked with known concentrations of PrPSc (18). Our data 
showed that 11 of the 14 samples analyzed were clearly detectable after 2 PMCA 
rounds (Figs. 3 and 4). By comparison with the spiked samples we estimate this to be 
equivalent to the amount of PrPSc present in a 10-9 dilution of the brain which 
extrapolates to about 5x10-13 g/ml. This concentration is similar to previous estimations 
using bioassays which indicated that the quantity of prions in blood is in the order of 1-
10 LD50 per ml of blood (7). Considering our previous estimation of the concentration of 
PrPSc excreted in urine of vCJD patients (16), we conclude that the concentration in 
blood is between 2 and 3 orders of magnitude higher than in urine.  
 
DISCUSSION      
So far, 229 cases of vCJD have been reported mostly in the UK and France (with 4 
cases in USA) and the future of this epidemic remains unknown. Fortunately, the 
spreading of classical BSE has been largely controlled, thanks to the implementation of 
feeding restrictions and surveillance (26-28). However, the appearance of atypical and 
genetic forms of BSE is an additional concern as the characteristics of transmission of 
these new forms may be different from traditional BSE (29-32). Nevertheless, it is 
estimated that millions of people have been exposed to BSE prions and it is currently 
unclear how many people may silently carry infectious material. Indeed, studies in 
transgenic mice models of human prion disease showed that infection with BSE prions 
frequently produces subclinical or carrier states, which upon a secondary infection can 
produce full-blown disease (3, 33, 34). Strikingly, a recent study searching for PrPSc 
immunoreactivity in archived surgically resected appendixes in the UK estimated that 
30,000 people in this country are asymptomatic carriers of vCJD infection (35). It is 
probable that this number is underestimated, since the methods used to detect prions in 
lymphoreticular specimens are unlikely to have 100% sensitivity. The possible existence 
of a large number of carriers of vCJD prions represents a significant risk for iatrogenic 
transmission of vCJD from human to human, a pathway that has already been shown to 
happen in other human prion diseases such as kuru and iatrogenic CJD (36). Iatrogenic 
transmission of vCJD through blood transfusion is perhaps the most significant concern 
because blood transfusion is a fairly common practice in medicine. Unfortunately this 
route has already proven to occur, since several cases have been linked to transfusion 
of blood donated by infected individuals at the pre-clinical stage of the disease (37-39). 
Although it is not known for certain that all subclinically infected individuals are able to 
infect others by means of blood transfusion, it is reasonable to assume this possibility 
as a precautionary principle. 
Currently there is no pre-mortem biochemical diagnosis for vCJD or any validated 
procedure to detect prions in blood or other human derived materials that might 
represent a concern for iatrogenic transmission of vCJD. Upon the onset of the first 
clinical abnormalities, people affected by vCJD die at an average of 2 years. The 
disease normally starts with psychiatric alterations (depression, anxiety, hallucinations) 
which are fairly common in other diseases and only begin to show more typical signs of 
a neurodegenerative condition (ataxia, myoclonus, dementia) several months after the 
first abnormalities. Even at this time the diagnosis of vCJD is very uncertain and is only 
confirmed by postmortem examination of the brain for the presence of prions with the 
vCJD signature and the associated brain abnormalities. Having a definitive diagnosis of 
vCJD at the early stages of the clinical disease is of utmost importance for differential 
diagnosis. Furthermore, early diagnosis of vCJD would allow any potential therapy to be 
given as soon as possible before substantial brain damage, which has been a problem 
with clinical trials in this group of diseases. It would also allow any public health 
measure to be implemented as soon as possible, e.g. tracing of any recipients of blood 
donated by an individual patient.  
Exciting recent progress in high sensitive detection of prions in biological fluids has 
been reported with the use of prion amplification techniques, including PMCA and RT-
QuIC (40, 41). Both PMCA and RT-QuIC take advantage of the prion conversion ability 
by seeding of protein misfolding to substantially amplify the signal and detect small 
amounts of PrPSc. Detection of PrPSc by RT-QuIC in cerebrospinal fluid (42, 43) and 
nasal brushings (44) is currently being employed in clinical diagnosis of sCJD.  
Unfortunately, much less work has been done with the application of RT-QuIC to vCJD 
and blood samples. Our current study demonstrates that small quantities of PrPSc are 
circulating in blood (both in plasma and associated with white cells) of all vCJD patients 
analyzed. These particles can be readily detectable by PMCA with 100% sensitivity and 
specificity. It is important to highlight the caveat that these estimations are based on a 
small number of vCJD blood samples analyzed (14 cases). Future double-blind studies 
are needed with a larger number of samples to allow statistical validation of the test. 
Nevertheless, although 14 samples may look little, it actually represents 6.1% of all the 
cases reported in the world since the appearance of vCJD more than 10 years ago. 
Furthermore, for many of the patients, samples were not collected or stored, and for 
many others the samples have been sequestered by regulatory health authorities to be 
used for validating potential commercial blood detection assays. 
Several pieces of evidence indicate that PrPSc might be present in blood of people 
infected, but not yet exhibiting the clinical symptoms of the disease. Indeed, various 
cases of vCJD were acquired by transfusion with blood taken from donors at the pre-
clinical stage of the disease (37-39). Since, PMCA has the capability to detect the 
equivalent of a single particle of PrPSc (17, 18), our findings suggest that PMCA may be 
useful as a pre-symptomatic non-invasive diagnosis of this disease. Supporting this 
conclusion, we have previously shown pre-clinical detection of prions in blood samples 
of animals experimentally infected with prion diseases (21). Also, and perhaps more 
importantly PMCA might be useful to identify prion contamination of the blood supply, 
which will minimize the iatrogenic spreading of this disease. Further studies need to be 
done to demonstrate the usefulness of PMCA for pre-symptomatic detection of vCJD 
prions and to investigate the earliest time during the pre-clinical phase of vCJD in which 
PrPSc is detectable in blood. 
In summary, our findings indicate that PMCA offers a great opportunity to detect PrPSc 
in blood of people infected by vCJD. This technology may have multiple practical 
applications, including disease diagnosis, blood banks safety, estimation of the possible 
pool of vCJD infection in the population, etc. The main limitations of our current study 
are the small number of samples analyzed, the fact that all samples were coming from 
people at later stages of the clinical disease and the lack of studies with blood samples 
from pre-symptomatic cases. The later is a very difficult task, since at this time it is not 
possible to identify people that have been infected with vCJD before the clinical 
symptoms of the disease are evident. Studies in non-human primates which have been 
experimentally infected with vCJD and blood samples collected longitudinally at various 
time points during the incubation period, offer the best alternative to analyze this 
possibility.      
METHODS 
Study design 
For this study we utilized blood samples from 14 vCJD patients and 153 controls, 
distributed as indicated below. Samples were obtained randomly without any exclusion 
or inclusion criteria other than the respective clinical diagnosis. Data reported included 
all samples analyzed. No samples or data were excluded after analysis.  Although this 
study was not done with blinded samples, we analyzed randomly many vCJD samples 
and controls at the same time, from initial centrifugation until western blot. The identity 
of the samples was seen only after the results were obtained. 
 
Patients samples 
Samples of frozen blood were collected at different stages of clinically diagnosed vCJD 
from 14 different patients. Twelve of the samples were collected in the UK and 2 of 
them in Italy. The disease was confirmed post-mortem by neuropathological and 
biochemical analysis. As controls we used four groups of whole blood samples, 
including 6 sCJD patients, 62 patients affected by other neurodegenerative diseases 
(Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and lewy bodies 
dementia), 26 patients affected by non-degenerative neurological disorders (vascular 
dementia, traumatic brain injury, stroke, epilepsy, encephalitis, and mood disorders) and 
49 healthy individuals (Table 1). Additionally, we analyzed 5 samples of plasma and 5 
white blood cells coming from different sCJD patients, adding up to 16 the total number 
of samples analyzed from sCJD. The diagnosis of sCJD was also confirmed post-
mortem by western blot and neuropathological analyses, while the diagnosis of other 
neurological diseases was determined clinically with the help of imaging and 
biochemical assays when available. Blood collection was approved by the respective 
Institutional Review Boards at the authors' centers.  
 
Processing of blood samples 
Samples of whole blood, and in some cases separated plasma or white cell fractions, 
were centrifuged to remove the bulk of proteins and other components that interfered 
with the PMCA reaction (Fig. 1). Briefly, 250 µl of sample was mixed and incubated with 
1 volume of 20% sarkosyl for 10 min at room temperature. Thereafter, samples were 
centrifuged at 100,000 x g during 1h at 4°C, supernatant was discarded and pellet 
washed in 250 µl of PBS. Tubes were centrifuged again at 100,000 x g for 30 mins at 
4°C. Pellet was resuspended directly in 10% brain homogenates from 
TgHuPrP(129MM), prepared as described below.  
 
PMCA procedure 
The PMCA reaction was carried out as previously described (16, 45), using as substrate 
brain homogenate from transgenic mice expressing human PrP with Met/Met genotype 
at position 129 (TgHuPrP(129MM)). These animals were kindly provided by Dr. Glenn 
Telling (Colorado State University). Brain substrate was prepared at a concentration of 
10% (weight/volume) in conversion buffer (PBS supplemented with 150 mM NaCl, 6mM 
EDTA, 0.05% digitonin and 1% Triton X-100) with protease inhibitors (Complete mini 
EDTA-free, Roche). Debris were removed by a low speed centrifugation (800 x g, 1 min, 
4°C) and brain homogenates were stored frozen at -80°C until further use. 
For PMCA, samples were subjected to a first round of 144 cycles of PMCA in 0.2 ml 
tubes (Eppendorf, cat. N. 951010022) containing 3 teflon beads (Hoover precision 
products). Each cycle consisted of 29 min and 30 s of incubation at 37/40°C followed by 
a 30 s pulse of sonication set at an amplitude of 30, using Qsonica microsonicator 
(Model Q700) equipped with a titanium horn. Subsequent rounds of 96 PMCA cycles 
were done by taking an aliquot of the amplified material which was diluted 10-fold into 
fresh TgHuPrP129MM brain homogenate. No multichannel pipette was used, to reduce 
risk of cross contamination. After each round of PMCA, samples were taken for 
detection of PrPSc using Western blot after digestion with proteinase K, as described 
(16, 45).  
 
Figure legends 
Figure 1. Schematic representation of the blood processing and PMCA 
procedure. To remove inhibitors of PMCA reaction, samples of whole blood (or 
separated blood components) were incubated with 1 volume of 20% sarkosyl. After high 
speed centrifugation, pellets were washed in PBS and centrifuged again. The new 
pellets were resuspended directly in 10% TgHuPrP(129MM) and placed in a 0.2 ml tube 
with 3 teflon beads. Samples were subjected to a first round of 144 PMCA cycles, 
followed by subsequent rounds of 96 PMCA cycles. PrPSc signal was detected by 
Western blots after proteinase K digestion. 
Figure 2. Optimization and limit of detection of vCJD PrPSc in blood. In order to  
optimize PrPSc detection by PMCA and determine the limit of detection, whole blood 
from a healthy person was spiked with vCJD brain homogenate at distinct final dilutions 
(10−4 to 10−11). After processing by high-speed centrifugation in the presence of sarkosyl 
(as described in Fig. 1), samples were subjected to various rounds of PMCA. The PrPSc 
signal was assessed by Western blot analysis after PK digestion. N refers to the normal 
(healthy) brain homogenate, used as migration control marker. Numbers in the left 
indicate the position of molecular weight markers. 
Figure 3. PrPSc detection in vCJD blood using PMCA. Representative samples of 
whole blood (250 µL) from 12 patients affected by vCJD, 5 healthy controls, 15 patients 
affected by other neurodegenerative and neurological disorders and 6 sCJD patients 
were subjected to 5 rounds of PMCA, as described in Methods. PrPSc signal was 
detected by Western blot after PK treatment. N refers to the transgenic mice normal 
brain homogenate without PK treatment used as migration control. Numbers in the left 
indicate the position of molecular weight markers. 
Figure 4. Detection of PrPSc in different blood fractions and at distinct times 
during the clinical disease. A. Samples of whole blood (WB), plasma (PL) and white 
blood cells (WBC) from 2 patients (#13 and #14) affected by vCJD and one healthy 
control were tested to analyze the presence of PrPSc in different blood fractions. Also 
whole blood from patient #13 was collected and tested at two different times during the 
clinical phase of the disease. Samples were processed and subjected to rounds of 
PMCA as described in Methods and Fig 1. The content of each lane is: 1, vCJD patient 
#13 plasma; 2, vCJD patient #14 plasma; 3, vCJD patient #14 WBC; 4, healthy control 
plasma; 5, vCJD patient #13 whole blood “a” (collected on 09/2002); 6, vCJD patient 
#13 whole blood “b” (collected on 11/2002);  7, healthy control WBC; 8, healthy control 
whole blood; 9, molecular weight standard. B. Samples of plasma (5) and WBC (5) from 
10 confirmed sCJD patients were centrifuged after incubation with sarkozyl and 
analyzed by a first round of 144 cycles of PMCA, followed by 4 rounds of 96 cycles 
each. In both panels, N refers to the transgenic mice normal brain homogenate without 
PK treatment used as migration control. Numbers in the left indicate the position of 
molecular weight markers 
Figure 5. Detection of PrPSc in small volume of blood and removal of pre-cleaning 
step. A. To  estimate the minimum volume of whole needed for blood detection, 
different volume of whole blood from 2 vCJD patients (samples #4 and 6) were directly 
added to a 10% brain homogenate from TgHuPrP(129MM). As positive controls we 
used healthy blood spiked with a 10-8 dilution of vCJD brain. Samples were subjected to 
3 sequential rounds of PMCA and PrPSc detected by Western blot. B. Samples of whole 
blood (100 µl) from 2 vCJD patients (#4 and 7), 5 healthy controls and two blood 
samples from controls spiked with 10-5 or 10-9 dilutions of vCJD brain homogenate were 
incubated with PMCA tubes containing 3 teflon beads for 1h at room temperature in an 
end-over-end mixer. The content was removed and 100 µL of PMCA substrate were 
added to the tube. Samples were subjected to various rounds of PMCA cycles and 
PrPSc was detected by Western blot after PK digestion. In both panels, N refers to the 
transgenic mice normal brain homogenate without PK treatment used as migration 
control and the numbers in the left indicate the position of molecular weight markers. 
 
Supplementary Materials 
Supplementary figure 1. Spiking of sCJD brain homogenate in blood. 
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